| Literature DB >> 35116517 |
Na Li1, Changpeng Zou1, Siming Gao1, Ying Guo1, Wei Wang1, Yan Guo1, Juan Zhang1, Cong Wang1, Yonghui An1.
Abstract
An inflammatory pseudotumor is considered a benign form of lesion marked by a proliferation of myofibroblasts with different degrees of inflammatory infiltrates. Pulmonary inflammatory pseudotumors (PIPs) are extremely rare in middle-aged adults. Normally, a PIP has a single lesion, and can be controlled constantly by surgery and drugs. In this paper, we report a case study of a 51-year-old male patient who presented with multiple inflammatory pseudotumors in lungs, thoracic spine, ribs, left humerusl, derived from PIPs throughout his body, which indicated a long disease term and significant recrudescence. After 6 surgeries (a wedge resection of the right lower lobe, a removal of three thoracic vertebral lesions, a removal of left humeral tumor lesion, a right lower lobe resection, local cryoablation of right lung, debridement of left upper-arm osteomyelitis and soft tissue infection), radiotherapy for lesions of left humerus destruction at a total dose of 20 Gy/10 F, and systematic treatments (30 mg prednisone acetate daily for 6 weeks, 50 mg compound cyclophosphamide tablets for 2 weeks; antibiotics, blood transfusions, nutritional support), his symptoms improved but reoccurred. The patient ultimately died of septic shock. Our case report highlights that the progression of a PIP to a malignant form requires further research. A multiple-lesion PIP that does not respond to systemic treatment can be highly dangerous. 2021 Translational Cancer Research. All rights reserved.Entities:
Keywords: Inflammatory pseudotumor; case report; inflammatory myofibroblastic tumor; lung tumor; pulmonary pseudotumor
Year: 2021 PMID: 35116517 PMCID: PMC8797402 DOI: 10.21037/tcr-21-564
Source DB: PubMed Journal: Transl Cancer Res ISSN: 2218-676X Impact factor: 1.241
Figure 1Typical CT images at different time points. (A) The postoperative CT scan on April 1st, 2013; (B) the chest CT scan performed on June 5th, 2013, after the patient was admitted to hospital for the 2nd time; (C) re-examination of the chest CT on June 27th after radiotherapy; (D) the chest CT scan performed on September 21st, 2013.
Blood indices at several key time points
| Timepoint | CRP (mg/L) | Hemoglobin (g/L) | RBC (109) | WBC (109) |
|---|---|---|---|---|
| 2013-01-16 | 148.4 | 101 | 3.72 | 9.7 |
| 2013-02-06 | 97.0 | 83 | 3.12 | 7.5 |
| 2013-02-20 | 90.6 | 92 | 3.51 | 10.6 |
| 2013-03-17 | 149.5 | 83 | 3.24 | 10.9 |
| 2013-03-23 | 95.1 | 88 | 3.41 | 11.5 |
| 2013-04-11 | 89.9 | 83 | 3.14 | 12.2 |
| 2013-06-05 | 113.4 | 69 | 3.08 | 16.2 |
| 2013-12-28 | 7.9 | 106 | 3.48 | 6.4 |
| 2015-03-27 | 61.6 | 90 | 3.6 | 4 |
| 2015-04-02 | 50.9 | 75 | 3.06 | 3 |
| 2015-04-27 | 97.9 | 75 | 2.85 | 4.3 |
| 2015-05-22 | 51.9 | 83 | 3.01 | 5.9 |
| 2015-06-10 | 96.4 | 103 | 4 | 17.1 |
CRP, C-reactive protein; RBC, red blood cells; WBC, white blood cells.
Tumor marker levels at several key time points
| Timepoint | CEA | AFP | CA199 | Total PSA | Free PSA |
|---|---|---|---|---|---|
| 2013-01-16 | 1.59 | 2.38 | 8.1 | 0.91 | 0.14 |
| 2013-06-05 | 1.19 | 2.06 | 7.6 | 0.38 | 0.07 |
| 2013-09-22 | 1.60 | 2.55 | 11.6 | 0.36 | 0.04 |
| 2013-11-06 | 1.44 | 2.69 | 4.9 | 0.25 | 0.05 |
| 2015-04-04 | 2.18 | 1.22 | 51.9 | 0.33 | 0.09 |
CEA, carcinoembryonic antigen; AFP, alpha fetoprotein, CA199, carbohydrate antigen 199; PSA, prostate specific antigen.